Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ortho-hydroxybenzoic acid or derivative doai
Reexamination Certificate
2011-05-03
2011-05-03
Gonzalez, Porfirio Nazario (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ortho-hydroxybenzoic acid or derivative doai
C514S449000, C514S452000, C514S162000, C514S159000, C549S200000, C549S454000, C549S357000, C560S019000
Reexamination Certificate
active
07935689
ABSTRACT:
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R1is alkyl having from 1 to 3 carbon atoms; R2is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R3and R4together are alkyl having two or three carbon atoms; or R3and R4are the same as each other and each is methyl or ethyl; R5is hydrogen or alkyl having from one to six carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or A is cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula (I) by a ring carbon. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
REFERENCES:
patent: 6858602 (2005-02-01), Sharma et al.
patent: 6916848 (2005-07-01), Sharma
patent: 6924314 (2005-08-01), Sharma et al.
patent: 6946491 (2005-09-01), Sharma et al.
patent: 7012071 (2006-03-01), Sharma et al.
patent: 7041659 (2006-05-01), Sharma
patent: 7045541 (2006-05-01), Sharma
patent: 7101910 (2006-09-01), Sharma
patent: 7329782 (2008-02-01), Sharma et al.
patent: 7361686 (2008-04-01), Hodge et al.
patent: 7442796 (2008-10-01), Sharma et al.
patent: 2005/0090555 (2005-04-01), Sharma et al.
patent: 2005/0256333 (2005-11-01), Sharma et al.
patent: 2006/0014784 (2006-01-01), Hodge et al.
patent: 2006/0035970 (2006-02-01), Hodge et al.
patent: 2006/0247309 (2006-11-01), Hodge et al.
patent: 2007/0105958 (2007-05-01), Sharma et al.
patent: 2007/0249696 (2007-10-01), Sharma et al.
patent: 2007/0249719 (2007-10-01), Sharma et al.
patent: 2007/0265322 (2007-11-01), Sharma et al.
patent: 2007/0282003 (2007-12-01), Sharma et al.
patent: 2008/0015209 (2008-01-01), Sharma et al.
patent: 2008/0015254 (2008-01-01), Sharma et al.
patent: 2008/0021109 (2008-01-01), Sharma et al.
patent: 2008/0027229 (2008-01-01), Hodge et al.
patent: 2008/0306150 (2008-12-01), Sharma et al.
patent: 2008/0306165 (2008-12-01), Sharma et al.
patent: 2009/0005451 (2009-01-01), Hodge et al.
patent: 0512352 (1992-11-01), None
patent: 02/100341 (2002-12-01), None
patent: 2004/073611 (2004-09-01), None
patent: 2004/091486 (2004-10-01), None
patent: 2006/127133 (2006-11-01), None
patent: 2007/087506 (2007-08-01), None
Mark et al., Polycystic ovary syndrome: pathogenesis and treatment over the short and long term, 2003, Cleveland Clinic Journal of Medicine, vol. 70, No. 1, pp. 31-45 (10 pages).
Calza et al, Insulin resistance and diabetes melitus in HIV-infected patients receiving antiretroviral therapy. 2004, Metabolic Syndrome and Related Disorders, 2(4): 241-250 (abstract only).
Chen et al., Lipodystrophy in human immunodeficiency virus-infected patients, 2002, J. Clin. Endocrinol Metab., 87: 4845-4856 (12 pages).
Adams et al., Treatment of Hyperlipidemia in nonalcoholic fatty liver disease: fat for thought, 2004, Indian Society of Gastroenterology, 23, 127-128 (2 pages).
Worman, H.J., Alcoholic liver disease, 1998, http://cpmcnet.columbia.edu/dept/gi/alcohol.html, electronic copy, (3 pages).
Younis, et al., “The prevention of type 2 diabetes mellitus: recent advances”, QJ Med., vol. 97, pp. 451-455, 2004.
Goff, et al., “Prevention of Cardiovascular Disease in Persons with type 2 diabetes Mellitus: Current Knowledge and Rational for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial”, AM J Cardiol., 99(12A): S4-S20, 2007. (Abstract).
Knowler, et al, “Perspectives in Diabetes: Preventing Non-Insulin-Dependent Diabetes”, Diabetes, vol. 44, pp. 483-488, 1995.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,515.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,520.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,560.
Pending (as of Jul. 14, 2008) claims from U.S. Appl. No. 12/160,857.
Pending (as of Jul. 28, 2008) claims from U.S. Appl. No. 12/162,397.
Pending (as of May 7, 2008) claims from U.S. Appl. No. 12/092,932.
Pending (as of Aug. 13, 2008) claims from U.S. Appl. No. 12/279,247.
Pending (as of Aug. 18, 2008) claims from U.S. Appl. No. 12/279808.
Pending (as of Sep. 25, 2008) claims from U.S. Appl. No. 12/294,530.
Pending (as of Dec. 9, 2008) claims from U.S. Appl. No. 12/304,007.
Pending (as of Feb. 13, 2009) claims from U.S. Appl. No. 12/377,460.
Sharma Shalini
von Borstel Reid W.
Cutliff Yate K
Gonzalez Porfirio Nazario
Kreisler Lewis J.
Wellstat Therapeutics Corporation
LandOfFree
Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2653055